What this topic covers
Subpart 1B (Dispense Medications) of the Content Outline effective June 1, 2022: labeling, packaging, refills, controlled substances, compounding, final verification and technicians. These are original practice notes, not documents of the California State Board of Pharmacy or PSI, based on law in force on January 1, 2027; time limits, thresholds and quantities can change with each year's legislation. Nothing here is medical advice.
Labels and packaging
- Physical description: color, shape and any identification code of the tablets or capsules (B&P Code section 4076(a)(11)).
- Patient-centered label: clustered items in at least a 12-point sans serif typeface (16 CCR section 1707.5(a)(1); as of January 1, 2027; check for later changes).
- Accessible label: at no additional cost, lasting for the duration of the prescription (B&P Code section 4076.8(a)).
- Alcohol warning: monoamine oxidase inhibitors, nitrates, and antidiabetic agents including insulin and sulfonylureas (16 CCR section 1744(b)).
- Special packaging: oral prescription drugs unless exempt, such as sublingual nitroglycerin (16 CFR 1700.14(a)(10)(i)).
Product selection and refills
- Biological products: record name and manufacturer within five days following dispensing (B&P Code section 4073.5(b); as of January 1, 2027; check for later changes).
- Emergency refill: tell the patient and inform the prescriber within a reasonable period of time (B&P Code section 4064).
- 90-day supply: after an initial 30-day supply, within the quantity authorized, on professional judgment; then notify the prescriber (B&P Code section 4064.5).
Controlled substances
- Schedule II, pharmacy short: remainder within 72 hours of the first partial filling, then a new prescription (21 CFR 1306.13(a); 16 CCR section 1745(d)).
- Other partial fills: 30 days at the patient's or prescriber's request (B&P Code section 4052.10(c)); 60 days for terminally ill and skilled nursing facility patients (16 CCR section 1745(c)); as of January 1, 2027; check for later changes.
- Schedule III and IV refills: no more than five refills and a 120-day supply in total (Health and Safety Code section 11200(b)); five refills is also the federal ceiling (21 CFR 1306.22(a)), and the stricter California cap prevails.
- Prescriber unavailable: a non-Schedule II refill in a reasonable amount until the prescriber can be contacted (Health and Safety Code section 11201).
- Transfers: Schedule III-V on a one-time basis only, pharmacist to pharmacist, unless a shared real-time online database (21 CFR 1306.25).
- Syringes: without a prescription to a person 18 years of age or older for personal use (B&P Code section 4145.5(b)).
Compounding and verification
- Beyond-use date: a date-only date expires at 11:59 p.m. on that date (16 CCR sections 1735.10(a) and 1736.14(b)).
- Compounding record: manufacturer, lot number and expiration date of each component (16 CCR section 1735.7(c)).
- Final verification: the pharmacist initials the label before the medication is provided (16 CCR section 1793.7(a)).
Technicians and automated systems
- Technician vaccine role: at least six hours of approved practical training and basic life support certification (B&P Code section 4115(b)(1)(A); as of January 1, 2027; check for later changes).
- Technician trainee: externship of 120 to 140 hours; one trainee per pharmacist at a time (B&P Code section 4115.5).
- Automated drug delivery system: owned or leased by the licensed pharmacy and part of it wherever located (B&P Code section 4427.4).
Sample questions (5)
1. A pharmacist at Sierra Valley Pharmacy, an outpatient pharmacy, is checking the label on a prescription for a long-marketed tablet.
The label shows the patient and prescriber names, drug name, strength and quantity, directions, date of issue, expiration date, and the pharmacy name, address and prescription number.
The tablet's description is on file in a commercial database.
Which additional item MUST appear on the label?
- The patient's date of birth and address
- The tablet's color, shape and imprint code
- The license number of the pharmacist on duty
- The DEA registration number of the prescriber
Business and Professions Code section 4076(a)(11) requires the physical description of the dispensed medication, “including its color, shape, and any identification code that appears on the tablets or capsules”, for outpatient pharmacies, and it may be printed on an auxiliary label. Section 4076(a) lists no patient date of birth, pharmacist license number or prescriber DEA number. None of the exemptions applies here: a veterinarian's prescription, a new drug in its first 120 days on the market, or a medication with no description in a commercially available database.
2. Under Business and Professions Code section 4076, the condition or purpose for which a drug was prescribed must appear on the label when it is:
- Stated on the prescription by the prescriber
- Requested by the patient's health plan
- Dispensed as a Schedule II controlled substance
- Discussed with the patient at the counter
Business and Professions Code section 4076(a)(10) requires the label to show the condition or purpose “if the condition or purpose is indicated on the prescription”. The requirement turns on what the prescriber wrote, not on a health plan request, the controlled-substance schedule of the drug, or counseling. Section 4076(a) lists none of those as triggers.
3. On a patient-centered label under 16 CCR section 1707.5, which item is listed immediately after the name of the patient in the clustered area?
- Directions for the use of the drug
- Condition or purpose of the drug
- Name and strength of the drug
- Quantity of the drug dispensed
16 CCR section 1707.5(a)(1) clusters four items in a set order: patient name, then drug name and strength, then directions for use, then condition or purpose. Directions and condition or purpose come later in that order. The quantity dispensed is one of the remaining elements of Business and Professions Code section 4076, which section 1707.5(a)(3) places outside the clustered area.
4. Under 16 CCR section 1707.5, the four items clustered in the patient-centered area of a label must be printed in at least which typeface?
- 8-point sans serif
- 10-point sans serif
- 11-point sans serif
- 12-point sans serif
16 CCR section 1707.5(a)(1) requires each clustered item to be printed in at least a 12-point sans serif typeface (regulation text as of January 1, 2027). The 8-point, 10-point and 11-point sizes fall below that minimum. The other label elements may appear in any style, font and size under section 1707.5(a)(3), so the minimum does not govern them.
5. A patient at Harbor View Pharmacy asks for translated directions for use. Her language is one for which the Board of Pharmacy has made translations available.
To comply with Business and Professions Code section 4076.6, the pharmacist should:
- Print the translation and remove the English directions
- Print the translation and keep English directions if possible
- Refer the patient to the Board's website for a translation
- Print the translation after the prescriber consents
Business and Professions Code section 4076.6(a) requires a dispenser to provide translated directions for use on request, with the English directions also on the container or label whenever possible. The dispenser may use the Board's translations under section 4076.6(b), so no referral is needed. Neither prescriber consent nor removal of the English directions is part of the requirement.